Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 million
RLYB•Second-quarter results
- Rallybio posted GAAP net income of USD 43.67 million for the quarter ended June 30, 2026, swinging from a net loss of USD 9.7 million a year earlier.
- GAAP operating loss narrowed 43.8% to USD 5.65 million, while revenue fell to no revenue from USD 212,000.
- GAAP other income rose to USD 50.64 million from USD 641,000, driven by a USD 50 million termination fee tied to the canceled Candid deal.
Cash position and merger plans
- Cash and cash equivalents totaled USD 92.8 million as of June 30, 2026; management expects this to fund operations for at least 12 months beyond the filing.
- Rallybio is pursuing a merger with Avenzo, alongside a planned USD 215 million concurrent financing, and expects to rename the combined company Avenzo Therapeutics.
